GSK slips Friday, underperforms market
GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.
Orocidin and Syngene Partner to Accelerate Biotech Innovation
“We are very impressed with Syngene’s professionalism, commitment to scientific excellence, and ability to deliver high-quality work on time,” said Allan Wehnert, CEO & Founder of Orocidin. “This ...
GSK rises Tuesday, outperforms market
GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.